Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRS8432
- Development stage
- Unknown
- Lead developer
- National Institutes of Health
01
Overview
MRS8432: sourced facts only. name: "Compound 30 (MRS8431) inhibited ABCG2-ATPase activity with IC50 160 ± 9 nM, while compound 40 (MRS8432) stimulated it potently with EC50 7.5 ± 2 nM." [PMID:41703909]; target: "Compound 30 (MRS8431) inhibited ABCG2-ATPase activity with IC50 160 ± 9 nM, while compound 40 (MRS8432) stimulated it potently with EC50 7.5 ± 2 nM." [PMID:41703909]; developer: "Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States." [PMID:41703909]
02
Targets
ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on MRS8432.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRS8432.